Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn
About

Company News Summary

Mayne Pharma Group Reports Net Loss of $133.98m for the Year to 30 June 2018

09 Oct 2018  |  20:34:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: Full Year Statutory Accounts

Mayne Pharma Group reported net loss of $133.98m for the year ended 30 June 2018. Revenue from ordinary activities were $5530m, down 7% from last year. Diluted EPS was (9.16) cents compared to 6.06 cents last year. Net operating cash flow was $121.5m compared to an outflow of $15.24m in the pcp. No dividend was declared.

Mayne Pharma Group Full Year Results to 30 June 2018

Year to 30 June 2018 ($A'000) Year to 30 June 2017 ($A'000)
Revenue 530,313 605,836
Pre-Tax Profit (Loss) (166,787) 115,935
Net Profit (Loss) (133,984) 88,567
Operating Cash Flow 121,498 (15,237)
Total Dividends (cents) nil nil
Diluted EPS (cents) (9)16) 6)06
NTA (cents) 12 5
Please click here for full details

See more ASX300 News Announcements